CALGB 80403 (Alliance)/E1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal Junction Cancers

Journal of Clinical Oncology

Volumn 34, Issue 23, 2016, Pages 2736-2742

  Enzinger, Peter C ^a   Burtness, Barbara Ann ^b,c   Niedzwiecki, Donna ^d   Ye, Xing ^d   Douglas, Kathe ^d   Ilson, David H ^e   Villaflor, Victoria Meucci ^f   Cohen, Steven J ^b,c   Mayer, Robert J ^a   Venook, Alan ^h   Benson, Al Bowen ^c,g   Goldberg, Richard M ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c AMERICAN COLLEGE OF RADIOLOGY   (United States)

^d DUKE UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL JUNCTION; GASTROESOPHAGEAL JUNCTION CANCER; HAND FOOT SYNDROME; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC ESOPHAGEAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SECONDARY; SURVIVAL RATE; TIME FACTOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 84981711242     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.5092     Document Type: Article

References (38)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Chau I, Norman AR, Cunningham D, et al: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: Pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395-2403, 2004
3. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006
5. Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19: 1450-1457, 2008
6. Kang YK, Kang WK, Shin DB, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 20:666-673, 2009
7. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 28:1547-1553, 2010
8. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997
9. Waters JS, Norman A, Cunningham D, et al: Long-Term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 80:269-272, 1999
10. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004, 2002
11. Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275, 1999
12. Ajani JA, Baker J, Pisters PW, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 94:641-646, 2002
13. Mauer AM, Kraut EH, Krauss SA, et al: Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16:1320-1325, 2005
14. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658-663, 2004
15. Chao Y, Yeh KH, Chang CJ, et al: Phase II study of weekly oxaliplatin and 24-h infusion of highdose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91:453-458, 2004
16. Louvet C, André T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548, 2002
17. Lordick F, Lorenzen S, Stollfuss J, et al: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93:190-194, 2005
18. De Vita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92:1644-1649, 2005
19. Kim DY, Kim JH, Lee SH, et al: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-Treated patients with advanced gastric cancer. Ann Oncol 14:383-387, 2003
20. Itakura Y, Sasano H, Shiga C, et al: Epidermal growth factor receptor overexpression in esophageal carcinoma: An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74:795-804, 1994
21. Torzewski M, Sarbia M, Verreet P, et al: The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. Anticancer Res 17:3915-3919, 1997
22. Yacoub L, Goldman H, Odze RD: Transforming growth factor-Alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-Associated neoplasia: Correlation with prognosis. Mod Pathol 10: 105-112, 1997
23. Gibson MK, Abraham SC, Wu TT, et al: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patientswith locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9: 6461-6468, 2003
24. Waddell T, Chau I, Cunningham D, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patientswith previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14:481-489, 2013
25. Erratum: Lancet Oncol 14:e254, 2013
26. Lordick F, Kang YK, Chung HC, et al: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol 14:490-499, 2013
27. Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457-1459, 1998
28. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
29. Gibbons J, Olkin I, Sobel M: Selecting and Ordering Populations: A New Statistical Methodology. New York, NY, John Wiley & Sons, 1977, p 103
30. Jung SH, Kim KM: On the estimation of the binomial probability in multistage clinical trials. Stat Med 23:881-896, 2004
31. Jennison C: Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 25:49-58, 1983
32. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [Ser A] 135: 185-207, 1972
33. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70, 1979
34. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
35. Greenwood M: The Natural Duration of Cancer: Reports on Public Health and Medical Subjects (vol 33). Her Majesty's Stationery Office, London, United Kingdom. 1926, pp 1-26
36. Janjigian YY, Ku GY, Campbell JC, et al: Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. Am J Clin Oncol 37:126-130, 2014
37. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
38. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009